Dongyangguang Pharmaceutical (06887.HK) is listed overall, reshaping the value of the leading pharmaceutical company with integrated research, production, and sales, and its market value is expected to quickly exceed 50 billion.

East Sunshine Pharma (06887.HK), which will be listed on the Hong Kong Stock Exchange on August 7th, will integrate its own research and development capabilities with the nationwide sales network of East Sunshine Changjiang Pharma after listing. This will form a research and development-production-sales loop, accelerate global operations, and promote value reshaping. According to the post-listing scale and current expectations for innovative drugs of East Sunshine Pharma, the market generally expects that its post-listing valuation is likely to exceed HK$50 billion.